CERo Therapeutics Holdings, Inc. (CERO)
CERo Therapeutics Holdings, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in South San Francisco, CA, US. The stock last traded at $0.01, down 1.92% on the session, giving a market capitalisation of $471,199. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of 0.16 implies it has historically moved less than the broad market.
CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
CERo Therapeutics Holdings, Inc. is most often compared with the following Healthcare names: